Oslo, Oct 1, 2018 - Navamedic ASA (OSE: NAVA) today announces that Tom Rönnlund
has tendered his resignation as CEO of Navamedic ASA and will leave the company
at the end of 2018 to take up a position with the Swedish probiotic company
Probi AB.
“Tom has been a driving force in the development of the company and leading it
through challenging times. The platform Tom has built together with the team
over the past three years puts us in a good position to further grow the
company. On behalf of Navamedic, I want to express my thanks to Tom for his
efforts and wish him success in his future endeavours” says Kathrine Gamborg
Andreassen, Chair of the Board.
Tom Rönnlund will join Probi AB, a Swedish publicly traded bioengineering
company.
“To leave Navamedic has been a very difficult decision. I am proud of what we as
a team have accomplished during a transformational period for the company. We
have positioned ourselves for a bright future through new and innovative growth
products with great potential and I am confident that the Navamedic team will
succeed in capitalizing on all the opportunities ahead of us,” says Tom
Rönnlund.
The search for a new CEO has been initiated and Rönnlund will remain CEO of
Navamedic until the end of 2018.